Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on the Safety and Efficacy of Targeted BCMA In Vivo LV Injection in the Treatment of Recurrent or Refractory Autoimmune Diseases

NCT07339540 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT07339540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07339540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on the Safety and Efficacy of Targeted BCMA In Vivo LV Injection in the Treatment of Recurrent or Refractory Autoimmune Diseases
Lead sponsor
Tongji Hospital
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 4, 2025
Completion date
October 30, 2028
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or refractory anca associated vasculitis, recurrent or refractory idiopathic inflammatory myopathy, recurrent or refractory igg4 related diseases, recurrent or refractory systemic lupus erythematosus, recurrent or refractory systemic sclerosis